4-甲氧基-8-氨基喹啉 | 59665-93-9

• 物质功能分类: 医药中间体 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-甲氧基-8-氨基喹啉
• 英文名称: 4-methoxyquinoline-8-amine
• 英文别名: 4-methoxy-8-aminoquinoline；8-amino-4-methoxyquinoline；4-methoxyquinolin-8-amine；4-methoxy-[8]quinolylamine；4-methoxy-quinolin-8-ylamine；4-Methoxy-[8]chinolylamin
• CAS: 59665-93-9
• 化学式: C₁₀H₁₀N₂O
• mdl: MFCD09261105
• 分子量: 174.202
• InChiKey: ILLFDHRDCAUCTG-UHFFFAOYSA-N

物化性质

• 熔点：
  107-107.5 °C
• 沸点：
  318.8±27.0 °C(Predicted)
• 密度：
  1.217±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-甲氧基-8-氨基喹啉 在 copper(l) iodide 、 铜 N-乙基吗啉 、 sodium hydroxide 、 sodium tetrahydroborate 作用下， 以 异丙醇 为溶剂， 反应 51.0h， 生成 4-methoxypyrido[2,3-a]phenazine-11-carboxylic acid
  参考文献：
  名称：

  Structure−Activity Relationships for Pyrido-, Imidazo-, Pyrazolo-, Pyrazino-, and Pyrrolophenazinecarboxamides as Topoisomerase-Targeted Anticancer Agents

  摘要：

  Heterocyclic phenazinecarboxamides were prepared by condensation of aminoheterocycles and 2-halo-3-nitrobenzoic acids, followed by reductive ring closure and amidation. They showed similar inhibition of paired cell lines that underexpressed topo II or overexpressed P-glycoprotein, indicating a non topo II mechanism of cytotoxicity and indifference to P-glycoprotein mediated multidrug resistance. Compounds with a fused five-membered heterocyclic ring were generally less potent than the pyrido[4,3-alpha]phenazines. A 4-methoxypyrido[4,3-alpha]phenazine (IC(50)s 2.5-26 nM) gave modest (ca. 5 day) growth delays in H69/P xenografts with oral dosing.

  DOI：

  10.1021/jm010330+
• 作为产物：
  描述：

  4,7-二氯-8-硝基喹啉 在 palladium 10% on activated carbon 氢气 、 ammonium formate 、 溶剂黄146 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 24.5h， 生成 4-甲氧基-8-氨基喹啉
  参考文献：
  名称：

  Novel Sulfonaminoquinoline Hepcidin Antagonists

  摘要：

  本发明涉及新型肝铁蛋白拮抗剂，包括它们的药物组合物以及将其用作药物治疗铁代谢紊乱，特别是铁缺乏病和贫血等疾病，特别是与慢性炎症性疾病相关的贫血。

  公开号：

  US20120214803A1

文献信息

• Ni‐Catalyzed Direct Carboxylation of Aryl C−H Bonds in Benzamides with CO ₂
  作者：Chunzhe Pei、Jiarui Zong、Bin Li、Baiquan Wang

  DOI：10.1002/adsc.202101285

  日期：2022.2

  The direct carboxylation of inert aryl C−H bond catalyzed by abundant and cheap nickel is still facing challenge. Herein, we report the Ni-catalyzed direct carboxylation of aryl C−H bonds in benzamides under 1 atm of CO2 to afford various methyl carboxylates or phthalimides, dealing with different post-processing. The reaction displays excellent functional group tolerance and affords moderate to high

  丰富且廉价的镍催化惰性芳基 C-H 键直接羧化仍面临挑战。在此，我们报道了在 1 个大气压的 CO 2下 Ni 催化的苯甲酰胺中芳基 C-H 键的直接羧化反应，得到各种羧酸甲酯或邻苯二甲酰亚胺，并进行了不同的后处理。该反应表现出优异的官能团耐受性，并在温和条件下提供中等至高的羧化产率。详细的机理研究表明，Ni(0)-Ni(II)-Ni(I) 催化循环可能参与该反应。
• Substituent-dependent fluorescent sensors for zinc ions based on carboxamidoquinoline
  作者：Yu Zhang、Xiangfeng Guo、Lihua Jia、Shicheng Xu、Zhihui Xu、Libo Zheng、Xuhong Qian

  DOI：10.1039/c2dt31139a

  日期：——

  A series of carboxamidoquinoline-based fluorescent sensors (the AQZ family) were synthesized and characterized. The AQZ family members were highly soluble in water and showed good selectivity for Zn2+via enhanced fluorescence in aqueous buffer solution. Fluorescence signals could be tuned from dual-wavelength ratiometric changes to changes in the intensity of a single wavelength upon binding Zn2+ through the introduction of different substituents onto the quinoline ring. Concentrations of free Zn2+ of 10−5–10−6 M could be detected using the sensors. Changes of substituents and their positions on the quinoline ring influenced the sensitivity for Zn2+, but had little effect on Zn2+ affinities.

  一系列基于羧酰胺喹啉的荧光传感器（AQZ家族）被合成并表征。AQZ家族成员在水中的溶解性很高，并通过在水中缓冲溶液中增强的荧光显示出对Zn²⁺的良好选择性。通过在喹啉环上引入不同的取代基，荧光信号可以在结合Zn²⁺时从双波长比率变化调整到单一波长强度的变化。使用这些传感器可以检测到10⁻⁵至10⁻⁶M的自由Zn²⁺浓度。取代基及其在喹啉环上的位置变化影响了它们对Zn²⁺的敏感性，但对Zn²⁺的亲和力影响不大。
• Visible-Light-Photocatalyzed Reductions of N-Heterocyclic Nitroaryls to Anilines Utilizing Ascorbic Acid Reductant
  作者：Aleksandar R. Todorov、Santeri Aikonen、Mikko Muuronen、Juho Helaja

  DOI：10.1021/acs.orglett.9b01205

  日期：2019.5.17

  A photoreductive protocol utilizing [Ru(bpy)3]2+ photocatalyst, blue light LEDs, and ascorbic acid (AscH2) has been developed to reduce nitro N-heteroaryls to the corresponding anilines. Based on experimental and computational results and previous studies, we propose that the reaction proceeds via proton-coupled electron transfer between AscH2, photocatalyst, and the nitro N-heteroaryl. The method

  已经开发出一种利用[Ru（bpy）3 ] 2+光催化剂，蓝光LED和抗坏血酸（AscH 2）的光还原方案，以将硝基N-杂芳基还原为相应的苯胺。根据实验和计算结果以及先前的研究，我们建议反应通过质子偶联的电子在AscH 2，光催化剂和硝基N-杂芳基之间转移而进行。该方法提供了一种绿色的催化程序，可以将例如4- / 8-硝基喹啉还原为相应的氨基喹啉，而后者是重要的抗疟疾药物中存在的亚结构。
• Pharmaceutical compounds
  申请人：——

  公开号：US20010034346A1

  公开（公告）日：2001-10-25

  A compound which is a heteroaromatic[a]phenazine carboxamide derivative of formula (I) 1 wherein X is a five- or six-membered heteroaromatic ring which contains one or two nitrogen atoms and which is unsubstituted or substituted by C 1 -C 6 alkyl, hydroxyl or C 1 -C 6 alkoxy; Q is C 1 -C 6 alkylene which is unsubstituted or substituted by C 1 -C 6 alkyl which is unsubstituted or substituted by a hydroxy group; and R 1 and R 2 which are the same or different are each C 1 -C 6 alkyl; or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of topoisomerase I and II and can be used to treat tumours, including tumours which express MDR.

  该化合物是公式（I）的杂环芳香基苯并吡嗪羧酰胺衍生物，其中X是一个含有一个或两个氮原子的五元或六元杂环芳香环，未取代或取代为C1-C6烷基，羟基或C1-C6烷氧基; Q是未取代或取代为C1-C6烷基（未取代或取代为羟基基团）的C1-C6烷基; R1和R2相同或不同，均为C1-C6烷基; 或其药学上可接受的盐。这些化合物是拓扑异构酶I和II的抑制剂，并可用于治疗肿瘤，包括表达MDR的肿瘤。
• Sulfonaminoquinoline hepcidin antagonists
  申请人：Vifor (International) AG

  公开号：US09102688B2

  公开（公告）日：2015-08-11

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型的赫普西丁拮抗剂，包括它们的药物组合物和将其作为药物用于治疗铁代谢紊乱的用途，特别是铁缺乏症和贫血，特别是与慢性炎症性疾病相关的贫血。